A ​U.S. ‌court on ​Monday ​allowed ⁠Eli ​Lilly to ​continue weight-loss ​drug ​advertisements that ‌rival ⁠Novo Nordisk ​claimed ​were ⁠false ​and ​misleading.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in